Results 51 to 60 of about 129,924 (203)

Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia [PDF]

, 1995
A number of studies have demonstrated the efficacy of oral anticoagulant therapy in reducing the risk of stroke and systemic embolism in patients with nonrheumatic atrial fibrillation.
Koudstaal, P.J. (Peter)
core   +5 more sources

Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation

BMC Cardiovascular Disorders, 2017
Background Rivaroxaban is an oral anticoagulant approved in the US for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF).
Faye L. Norby, Lindsay G.S. Bengtson, Pamela L. Lutsey, Lin Y. Chen, Richard F. MacLehose, Alanna M. Chamberlain, Ian Rapson, Alvaro Alonso   +7 more
doaj   +1 more source

Edoxaban: an update on the new oral direct factor Xa inhibitor. [PDF]

, 2014
Edoxaban is a once-daily oral anticoagulant that rapidly and selectively inhibits factor Xa in a concentration-dependent manner. This review describes the extensive clinical development program of edoxaban, including phase III studies in patients with ...
A. John Camm, AC Skanes, AG Turpie, AJ Camm, AK Kakkar, AT Cohen, B Laulicht, BF Gage, BI Eriksson, BI Eriksson, BI Eriksson, BI Eriksson, BS Stambler, C Kearon, CB Granger, CT Ruff, DE Salazar, G Agnelli, G Agnelli, G Lu, G Raskob, G Raskob, H Masumoto, H Zahir, Henri Bounameaux, J Mendell, J Mendell, J Mendell, J Mendell, J Mendell, J Mendell, J Stampfuss, JH Alexander, JI Weitz, JL Mega, K Ogata, KL Furie, LT Grip, M Crowther, M Hori, M Pirmohamed, MR Lassen, MR Lassen, MR Lassen, MR Lassen, MR Patel, MS Bathala, MU Zafar, N Chung, N Matsushima, R Caterina De, R Caterina De, RP Giugliano, S Kaatz, S Schulman, S Schulman, S Schulman, SE Kimmel, SJ Connolly, SJ Connolly, SJ Connolly, SZ Goldhaber, T Fuji, T Fuji, T Fukuda, T Hulle van der, T Mikkaichi, T Wilke, T Yamashita, TI Verhoef, W Mueck, Y Falck-Ytter, Y Kuroda   +72 more
core   +1 more source

Testing for inherited thrombophilia does not reduce the recurrence of venous thrombosis\ud [PDF]

, 2008
Background: Inherited thrombophilia is only weakly associated with recurrence in patients with a first venous thrombosis (VT). In spite of this, thrombophilia testing is often performed in these patients. Positive results may influence patient management
Coppens, M., Doggen, C.J.M., Middeldorp, S., Reijnders, J.H., Rosendaal, F.R.   +4 more
core   +2 more sources

Direct oral anticoagulant: Looking beyond convenience

Annals, Academy of Medicine, Singapore
Since the 2010 Food and Drug Administration approval of Dabigatran as the first non-vitamin-K antagonist oral anticoagulants or direct oral anticoagulants (DOACs) as it is now more commonly referred to, there has been much development in the field with ...
Samuel Ji Quan Koh, Jonathan Jiunn Liang Yap   +1 more
doaj   +1 more source

Provider Specialty, Anticoagulation Prescription Patterns, and Stroke Risk in Atrial Fibrillation

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2018
BackgroundDifferences in anticoagulation rates and direct oral anticoagulant use by provider specialty may identify an area of practice improvement to reduce future stroke events in patients with atrial fibrillation (AF).
Wesley T. O'Neal, Pratik B. Sandesara, J'Neka S. Claxton, Richard F. MacLehose, Lin Y. Chen, Lindsay G. S. Bengtson, Alanna M. Chamberlain, Faye L. Norby, Pamela L. Lutsey, Alvaro Alonso   +9 more
doaj   +1 more source

Factors influencing primary care physicians’ prescribing behavior of anticoagulant therapy for the management of patients with non-valvular atrial fibrillation in Singapore: a qualitative research study

BMC Family Practice, 2021
Background Oral anticoagulant therapy use in patients with atrial fibrillation (AF) remains suboptimal in Singapore, despite the availability of both warfarin and non-vitamin K antagonist oral anticoagulants (NOACs).
Shera Chaterji, Lay Geok Lian, Ting Yee Lee, Liwei Chua, Sabrina Yi-Mei Wee, Sui Ling Yap, Dhana Letchimy K, Ngiap Chuan Tan   +7 more
doaj   +1 more source

New oral anticoagulants and their reversal agents [PDF]

, 2018
Atrial fibrillation is a commonly encountered pathology in medical practice, and its prevalence has shown a continuous rise over the past years. Atrial fibrillation has a significant impact on patients\u27 quality of life, not only due to the standard ...
Bodean, Oana, Diaconu, Camelia C, Laslo, Crista L, Marcu, Dragos, Neagu, Tiberiu P, Paduraru, Dan N, Pantea Stoian, Anca, Socea, Bogdan, Socea, Laura I, Stanescu, Ana Maria Alexandra   +9 more
core   +1 more source

Influence of vitamin K antagonist treatment on activated partial thromboplastin time [PDF]

, 2015
A
Devreese, Katrien, MULLIEZ, SYLVIE, Van den Bogaert, Julie   +2 more
core   +2 more sources

Cancer-Associated Thrombosis in Cirrhotic Patients with Hepatocellular Carcinoma. [PDF]

, 2018
It is common knowledge that cancer patients are more prone to develop venous thromboembolic complications (VTE). It is therefore not surprising that patients with hepatocellular carcinoma (HCC) present with a significant risk of VTE, with the portal vein
Burra, P, Campello, E, Russo, Fp., Simioni, P, Spiezia, L, Zanetto, A   +5 more
core   +1 more source